ANALGESIC AND MUSCLE RELAXANT CAPLETS TABLET
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
09-01-2013
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
IBUPROFEN; METHOCARBAMOL
Beschikbaar vanaf:
TEVA CANADA LIMITED
ATC-code:
M03BA53
INN (Algemene Internationale Benaming):
METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS
Dosering:
200MG; 500MG
farmaceutische vorm:
TABLET
Samenstelling:
IBUPROFEN 200MG; METHOCARBAMOL 500MG
Toedieningsweg:
ORAL
Eenheden in pakket:
18/40
Prescription-type:
OTC
Therapeutisch gebied:
CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS
Product samenvatting:
Active ingredient group (AIG) number: 0248961001; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2021-08-12
Productkenmerken
1 | P a g e
PRODUCT MONOGRAPH
ANALGESIC & MUSCLE RELAXANT CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
TEVA CANADA LIMITED
Date of Preparation:
30 Novopharm Court
January 8, 2013
Toronto, Canada
M1B 2K9
Control# 161025
2 | P a g e
TABLE OF CONTENTS
Clinical Pharmacology
..............................................................................................................................
3
Indications:
................................................................................................................................................
7
Contraindications
......................................................................................................................................
8
Warnings:
..................................................................................................................................................
8
Precautions
..............................................................................................................................................
12
Drug Interactions
....................................................................................................................................
13
Adverse Reactions
..................................................................................................................................
15
Symptoms and Treatment of Overdose
...................................................................................................
17
Dosage and
Administration.....................................................................................................................
18
Pharmaceutical Information
....................................................................................................................
19
Composition:
...........................................................................................................................................
21
Availability of Dosage Forms
..........................
Lees het volledige document
